NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) for violations of the federal securities laws on behalf of investors who purchased or acquired Altimmune common stock between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”). On May 6, 2024, a complaint was filed against the Company and ...

NEW YORK, May 30, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission ...

NEW YORK, May 29, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), of the important July 5, 2024 lead plaintiff deadline.SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NE ...

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20 a.m. Eastern ...

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20 a.m. Eastern ...

NEW YORK, May 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=81730&from=4CLASS PERIOD: December 1, 2023 to April 2 ...

LAS VEGAS, May 28, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) a multidisciplinary organization with a focus on healthcare and fintech, announced today that its Fintech subsidiary, ALT 5 Sigma, will be presenting at the iFX Expo, the World's largest online trading conference and tradeshow held on June 18 until June 20 in Limassol, Cyprus. https://cyprus2024.ifxexpo.com/The iFX Expo brings together thousands of C-Level Executives and Industry Peers from 120 countries. The Online Trading Platform Market wa ...

Group 1: Penny Stocks Overview - The penny stock market presents multiple overlooked investment opportunities, particularly with macroeconomic tailwinds expected in the second half of 2024, including potential interest rate cuts by the Fed [1] - Not all penny stocks are strong investments, but certain companies discussed have more positives than negatives, warranting attention [1] Group 2: Altimmune (ALT) - Altimmune is positioned as a promising player in the weight loss drug sector, particularly due to its pemvidutide, which results in a 25.5% decrease in lean muscle mass, significantly less than the nearly 40% decline associated with competitors' drugs [2][3] - The ability to maintain muscle mass during weight loss is crucial for health, especially in elderly populations, making muscle-preserving weight loss drugs a key area of interest [3] Group 3: Grab Holdings (GRAB) - Grab Holdings is emerging as a super app with strong revenue growth of 24%, resulting in sales of $653 million, and has narrowed its operating loss by $129 million [5] - The company has raised its 2024 EBITDA prediction from $180 million to a range of $250 to $270 million, reflecting confidence in its performance [5] - Grab's strategic focus on fintech is yielding lower payment costs and contributing to its growth in Southeast Asia [5] Group 4: Lithium Americas (LAC) - Lithium Americas is developing the Thacker Pass lithium deposit in Nevada, which is set to become the largest lithium project in history, with full production expected by 2028 [6] - The Thacker Pass deposit has an estimated mine life of over 40 years and has attracted significant investment, including $650 million from General Motors and a $2.26 billion loan from the Department of Energy [6] - There is potential for share prices to quadruple or quintuple in the next 12 to 18 months, indicating strong future growth prospects [7]

Mykola Sosiukin/iStock via Getty Images Altimmune Inc. (NASDAQ:ALT) is completing a Phase 2 clinical trial of pemvidutide, an anti-obesity drug that appears to be able to bring important benefits to weight loss. The differentiating element compared to the competition seems to be the drug's ability to attack 74.5% fat mass and, if confirmed in the next phase 2 and phase 3 steps, could create a competitive moat against already approved drugs that act on the same GLP-1 hormone. The market prospects appear ...

NEW YORK, May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between December 1, 2023 and April 26, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission ...